Company / Revenue
Viridian Therapeutics, Inc.\DE Revenue History
FY2016-FY2017 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$462.0K
FY2017
5-year range
-
FY2016-FY2017
Trend
-86.7%
vs FY2016
Sector context
#147 of 155
Health Care
What the data says
Among 155 Health Care companies, Viridian Therapeutics, Inc.\DE is in the bottom 5% for revenue.
Based on SEC 10-K filings.
$462,000 in FY2017.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 155This company $462.0K Sector average $4.5B
▼
-100.0% below sector average
Key checks
Key Insights
- In FY2017, revenue decreased 86.7% year-over-year.
- Ranks #147 out of 155 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | $462.0K | -86.7% |
| FY2016 | $3.5M | -39.1% |
As of FY2017 · SEC 10-K · Updated Jun 30, 2026